Mentions
Extended reach
Total likes
Video views
AI synopsis
The social discussions extensively highlight the trial’s positive outcomes, such as 'reduced VTE recurrence from 10% to 1.3%', and use language like 'benefit', 'remarkable', and 'practice-changing' to convey excitement and significance. The tone reflects a focus on clinical impact and implications for treatment guidelines, indicating a high level of engagement and recognition of the trial’s importance.
Most discussions specifically support the findings of the trial, emphasizing the benefits of low-dose apixaban in preventing recurrent VTE and highlighting key results like reduced risk and low bleeding rates.
The social discussions clearly demonstrate high interest, with numerous mentions of the trial's significance, detailed results, and potential practice changes, indicating engagement with the research topic.
Many posts reference specific trial results, clinical implications, and trial leadership, showing thoughtfulness and depth, although some are more generalized, resulting in a moderate engagement score.
Given the emphasis on practice-changing results, dissemination at a major congress, and inclusion in a prominent journal, the discussions suggest substantial potential impact on clinical guidelines and practice.
Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care https://t.co/IdJp3T20rM #ESCCongress | @escardio https://t.co/C55yCySJzf
Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care https://t.co/IdJp3T20rM #Hematology https://t.co/djXZWMdglw
New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Apixaban for Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Measurable Residual Disease–Guided Therapy for CLL https://t.co/8e5qUOXjY6
Apixaban for Extended Treatment of Provoked Venous Thromboembolism. #NEJM "Low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding." https://t.co/7rIrMATAZh https://t.co/yM15y9HRgy
2| HI-PRO For provoked VTE standard tx is 3 months but what if has ongoing risks (ie autoimmune dz, obesity)? In a single-center RCT extended low-dose apixaban (2.5mg BID) reduced recurrent VTE vs placebo at 1 year (NNT=10) KM curves still diverging https://t.co/qGgiBN0LLW https://t.co/rBGgkd9uDI
Way to go @AntoineBejjani_
A bold trial in valvular heart disease and a cardiovascular prevention trial highlight the importance of humility in medical practice. Discussing new approaches to TAVI, CV risk management, and the impact of full…
Prof. Bikdeli and Prof. Didier discuss the HIPRO study on extended treatment of provoked venous thromboembolism, presented at the 2025 European Society of Cardiology meeting. The study compares rivaroxaban monotherapy…
RT @SinaRsh: Honored to be a part of the HI-PRO trial, presented today by my mentor @GregoryPiazza4 at #ESCCongress2025 Published @NEJM…
كذلك هناك دراسة HI-PRO للمرضى الغير مصابين بالسرطان وعلى نفس المبدىء تم استخدام Apixaban 2.5 mg وكانت النتائج ايجابية حيث انها تحمي من حدوث خثرات اخرى وتقلل النزف. https://t.co/7MsFFYrBhZ https://t.co/G80D61gaqR
HI-PRO試験 平均59歳の手術など誘因のあるDVT/PE患者の中で一つ以上血栓リスク(肥満、炎症性疾患、心不全、ASCVD etc.)がある患者に少量DOACを止めずに長期投与すると、1年でRRR 87%、ARR 3.1%の血栓リスク減少。大出血は増えず、非大出血が HR 2.68(2.0%) https://t.co/sG3zkURKCf
今年の抗血栓療法のRCT PRESTIGE-AF：https://t.co/QPfJ2IlHJe ALONE-AF：https://t.co/ICHGgPJHLY HI-PRO：https://t.co/uYQodwQjC1 ATIS-NVAF：https://t.co/19RiR5Xeyc AFIRE(事後解析)：https://t.co/LygppyGCtq
Apixaban (2.5 mg) may benefit VTE patients post-3-month anticoagulation with enduring risk factors. Results from a randomized trial. PMID:40888734, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2509426 #Medsky #Pharmsky #RNA #ASHG #ESHG
Apixaban (2.5 mg) may benefit VTE patients post-3-month anticoagulation with enduring risk factors. Results from a randomized trial. PMID:40888734, N Engl J Med 2025, @NEJM https://t.co/x9Oq4LmbPF #AI #Pharma #BioMed #RNA #ASHG #ESHG
En TEV provocada con riesgo persistente, apixabán a baja intensidad 12 meses redujo TEV recurrente sintomática vs placebo, con bajo riesgo de sangrado mayor. https://t.co/FCEnEfA4N6?
RT @OPCILive: Watch the latest OPCI Journal Club featuring @GregoryPiazza4 presenting “Apixaban for Extended Treatment of Provoked Venous…
Watch the latest OPCI Journal Club featuring @GregoryPiazza4 presenting “Apixaban for Extended Treatment of Provoked Venous Thromboembolism.” Along with esteemed panelists @djc795 @JWMoses @DrAllenJ and Dr. Kiran Reddy. https://t.co/zZn7TtGeoP https://t.co/r7NyXGHFeo
Low-dose apixaban for 12 months slashed recurrent VTE risk in patients with provoking factors, with minimal bleeding complications. by Piazza G, Bikdeli B (...) Goldhaber SZ et 16 al. in N Engl J Med #MedSky
Low-dose apixaban for 12 months slashed recurrent VTE risk in patients with provoking factors, with minimal bleeding complications. by Piazza G, Bikdeli B (...) Goldhaber SZ et 16 al. in N Engl J Med https://t.co/nCXd5S9P0f #MedX #MedResearch
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @imedverse: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. #NEJM "Low-intensity therapy with apixaban for 12 mont…
Apixaban for Extended Treatment of Provoked Venous Thromboembolism. #NEJM "Low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding." www.nejm.org/doi/full/10....
Apixaban for Extended Treatment of Provoked Venous Thromboembolism. #NEJM "Low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding." https://t.co/7rIrMATAZh https://t.co/yM15y9HRgy
Among patients with provoked VTE and enduring risk factors, low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding. @NEJM https://t.co/oANyHrLOcA https://t.co/nytdfs7jMX
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @Bitscopic:
In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary: nej.md/4p6tIDo
RT @richardhirschs1: ⚠️Reported in @NEJM today: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. After a provoked DVT…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
Provoked VTEに対する抗凝固療法3ヶ月後、さらにエリキュースを1年間内服することでVTEリスクが低下（1.3% vs 10.0%、HR 0.13）。 Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/IWN3u1wVkQ https://t.co/eXK292MIPx
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Ed…
Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care https://t.co/IdJp3T20rM #Hematology https://t.co/djXZWMdglw
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
RT @JohannaSeidenMD: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/a9mK…
RT @richardhirschs1: ⚠️Reported in @NEJM today: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. After a provoked DVT…
RT @richardhirschs1: ⚠️Reported in @NEJM today: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. After a provoked DVT…
⚠️Reported in @NEJM today: Apixaban for Extended Treatment of Provoked Venous Thromboembolism. After a provoked DVT standard practise is to treat patients with blood thinners like apixaban for 3 to 6 months. This trial confirms that continuing low dose apixaban out to a year https://t.co/vRWDc1Jcjr
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
RT @NEJM: New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co…
New in the September 25, 2025, issue of NEJM: Digitoxin in Heart Failure with Reduced EF (DIGIT-HF phase 4 trial) https://t.co/8mpwOpVo7U Apixaban for Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Measurable Residual Disease–Guided Therapy for CLL https://t.co/8e5qUOXjY6
RT @sgoto4: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/jjrfnoLDwR 静脈…
RT @sgoto4: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/jjrfnoLDwR 静脈…
RT @sgoto4: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/jjrfnoLDwR 静脈…
RT @sgoto4: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/jjrfnoLDwR 静脈…
(NEJM) Seguridad y eficacia del tto prolongado con apixabán en pac con TEV https://t.co/sSRsbHCAbL ECA https://t.co/ie5eNctASH
RT @JohannaSeidenMD: Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/a9mK…
For patients with a provoked VTE but enduring risk factors, this trial offers a clear path. Extending therapy with low-dose apixaban for 12 months cut recurrent VTE risk from 10.0% to just 1.3% vs. placebo, with a low incidence of major bleeding. https://t.co/3duwdPJHzC
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/jjrfnoLDwR 静脈血栓症の長期治療には抗凝固薬減量が理にかなっている
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/a9mKUKIs9h
RT @drbennisahmed: Apixaban for Extended Treatment of Provoked Venous Thromboembolism Among patients with provoked VTE and enduring risk f…
RT @drbennisahmed: Apixaban for Extended Treatment of Provoked Venous Thromboembolism Among patients with provoked VTE and enduring risk f…
Apixaban for Extended Treatment of Provoked Venous Thromboembolism Among patients with provoked VTE and enduring risk factors, low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding https://t.co/UaVWtyiD7A
@escardio Bottom Line: Extended low-dose apixaban significantly reduces recurrent VTE in patients with provoked VTE + enduring risk factors, with low major bleeding risk. This will likely change practice and guidelines. https://t.co/1ryPLBgxHy 8/8
RT @AnilMakam: 2| HI-PRO For provoked VTE standard tx is 3 months but what if has ongoing risks (ie autoimmune dz, obesity)? In a singl…
Apixaban significantly reduces symptomatic recurrent VTE risk in patients with transient triggers and enduring risk factors, with minimal bleeding. by Piazza G, Bikdeli B (...) Goldhaber SZ et 16 al. in N Engl J Med https://t.co/nCXd5S9P0f #MedX #MedResearch
2| HI-PRO For provoked VTE standard tx is 3 months but what if has ongoing risks (ie autoimmune dz, obesity)? In a single-center RCT extended low-dose apixaban (2.5mg BID) reduced recurrent VTE vs placebo at 1 year (NNT=10) KM curves still diverging https://t.co/qGgiBN0LLW https://t.co/rBGgkd9uDI
【RCT】永続的なリスク因子を1つ以上もち、一時的な誘因のある静脈血栓塞栓症患者での最低3か月の抗凝固療法完了後のアピキサバン1回2.5mg1日2回投与は、プラセボ投与と比較して、症候性静脈血栓塞栓症再発を減少させた。 #ペ読 https://t.co/KnZ5ZG52XP
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine www.nejm.org/doi/full/10....
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/Mm1xLMCypQ
RT @FarmaMadridAP: (NEJM) Apixabán para el tratamiento prolongado del TEV https://t.co/0mI3OY8Yfx ✅Resultados: <riesgo TEV recurrente sinto…
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/lnPo5yB6XQ Will you change your practice ?
RT @PittIMChiefs: Way to go @AntoineBejjani_
RT @PittIMChiefs: Way to go @AntoineBejjani_
(NEJM) Apixabán para el tratamiento prolongado del TEV https://t.co/0mI3OY8Yfx ✅Resultados: <riesgo TEV recurrente sintomático vs placebo, con bajo riesgo hemorragia grave.
Excelente artículo aunque no se puede generalizar con todos los pacientes! Otro salto en la MBE Apixaban para el tratamiento Apixaban para el tratamiento prolongado del tromboembolismo venoso provocado | New England Journal of Medicine https://t.co/3FXLIO4XUI
一過性誘因＋持続的リスク因子を有するVTE患者600人を対象としたRCT（HI-PRO）では，抗凝固3か月後にアピキサバン2.5mgを12か月継続するとプラセボより再発VTEを減らした（1.3％対10.0％，HR 0.13，0.04～0.36）．大出血は各群0～1例． https://t.co/YAzlVxDzD8
RT @MarcCarrier1:
RT @PittIMChiefs: Way to go @AntoineBejjani_
Way to go @AntoineBejjani_
RT @SinaRsh: Honored to be a part of the HI-PRO trial, presented today by my mentor @GregoryPiazza4 at #ESCCongress2025 Published @NEJM…
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
Apixaban for Extended Treatment of Provoked Venous Thromboembolism | New England Journal of Medicine https://t.co/oMW0TH7sQd
Apixaban for Extended Treatment of Provoked Venous Thromboembolism #science #publication #research #publications https://t.co/n66a4npJCq
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
RT @gunnar_heine: At the end of a perfect #ESCCongress2025 day: People with provoked VTE benefit from extended treatment with low-dose Apix…
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
RT @juanjolopezn: Apixaban for Extended Treatment of Provoked Venous Thromboembolism @NEJM #VTE #apixaban https://t.co/p7CFKrfU1r
RT @MarcCarrier1:
RT @SinaRsh: Honored to be a part of the HI-PRO trial, presented today by my mentor @GregoryPiazza4 at #ESCCongress2025 Published @NEJM…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @flora_peyvandi: Among patients with provoked VTE and enduring risk factors, #low -intensity therapy with A#apixaban for 12 months resul…
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
Among patients with provoked VTE and enduring risk factors, low-intensity therapy with apixaban for 12 months resulted in a lower risk of symptomatic recurrent VTE than placebo, with a low risk of major bleeding. https://t.co/1DP9JIFP1H
RT @SinaRsh: Honored to be a part of the HI-PRO trial, presented today by my mentor @GregoryPiazza4 at #ESCCongress2025 Published @NEJM…
RT @MarcCarrier1:
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
Apixaban for Extended Treatment of Provoked Venous Thromboembolism @NEJM #VTE #apixaban https://t.co/p7CFKrfU1r
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @MarcCarrier1:
RT @MarcCarrier1:
RT @bbikdeli: Absolutely incredible @GregoryPiazza4 leading this @NEJM @MGBResearchNews #RCT!!
RT @MarcCarrier1:
RT @MarcCarrier1:
RT @MarcCarrier1:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @DrPascalMeier:
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
RT @NEJM: Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Edi…
Original Article: Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) https://t.co/Epe4Q957pV Editorial: Art within Evidence — Balancing Anticoagulant Duration in VTE Care https://t.co/IdJp3T20rM #ESCCongress | @escardio https://t.co/C55yCySJzf
RT @CordobaETV: ✅ APIXABAN EN EL TRATAMIENTO EXTENDIDO DE LA ETV PROVOCADA. NEJM 2025
RT @CordobaETV: ✅ APIXABAN EN EL TRATAMIENTO EXTENDIDO DE LA ETV PROVOCADA. NEJM 2025
Apixaban for Extended Treatment of Provoked Venous Thromboembolism (HI-PRO trial) nej.md/4p6tIDo
“Apixaban for Extended Treatment of Provoked Venous Thromboembolism.” Présenté ce jour a #ESCCongress et publié dans le @nejm.org. #MedSky #ESC2025 www.nejm.org/doi/full/10....
✅ APIXABAN EN EL TRATAMIENTO EXTENDIDO DE LA ETV PROVOCADA. NEJM 2025
RT @ESCardioNews: Dr. Gregory Piazza presents: “HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism”
Dr. Gregory Piazza presents: “HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism”
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más actualizaciones cada semana ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más actualizaciones cada semana ...
WELCOME TO EVERYONE The purpose of this group is to provide information to Internists about new developments in clinical medicine and practice...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
... Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025;393(12):1166-1176. doi:10.1056/NEJMoa2509426.
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ... NEJMoa2509426 Guarda este reel para tus guardias y compártelo ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
... 10.1056/NEJMe2510701. https://www.nejm.org/doi/full/10.1056/NEJMoa2509426. I like medical news… but only when it's interesting. So I'll try ...
... 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
Since the late 1950s, the diagnosis of chronic liver disease and the staging of fibrosis have relied on liver biopsy, an invasive procedure with ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
आपकी सबमिशन के लिए धन्यवाद! कृपया निम्नलिखित को पढ़ें। अपनी रिक्वेस्ट मिलने के बाद पूर्ति करने वाले को "धन्यवाद समाधान सत्यापित" के साथ जवाब दें। संभावना है कि आप ...
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
https://www.nejm.org/doi/abs/10.1056/NEJMoa2509426.
... patients with provoked events + ongoing risk factors. Source: N Engl J Med, August 30, 2025 DOI: 10.1056/NEJMoa2509426.
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509426. Epub ahead of print.
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2509426. Epub ahead of print.
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
10.1056/NEJMoa2509426. Keywords. /Health and medicine/Medical specialties/Cardiology. EurekAlert! The Global Source for Science News. AAAS ...
DOI: 10.1056/NEJMoa2509426. Journal information: New England Journal of Medicine. Provided by European Society of Cardiology. + Explore further ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
HI-PRO Results from #ESCCongress: At one year, low-intensity apixaban therapy results in lower risk of symptomatic recurrent VTE compared to ...
... 10.1056/NEJMoa2509426. Secondary Source. New England Journal of Medicine. Source Reference: Zakai NA "Art within evidence -- Balancing ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
HI-PRO: https://www.nejm.org/doi/full/10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en ...
Renata PLC has received UK-MHRA approval for Apixaban 2.5mg and 5mg Tablets for the prevention of venous thromboembolism (VTE) after hip or ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
Morbo di Buerger: l'ultima sigaretta e poi basta - EMpills - Pillole di medicina d'urgenza. Descrizione di un caso clinico di una paziente ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y compártelo con quien esté rotando en cardio. Sígueme para más ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
... 10.1056/NEJMoa2509426 Guarda este reel para tus guardias y ... 10.1056/NEJMoa2415471 Guidelines Enfermedad Valvular: https://www ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
https://www.nejm. org/doi/full/10.1056/NEJMoa2416112?query=TOC · No photo description available. Jose Luis Santamaria and 21 others ·
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
org/doi/full/10.1056/NEJMoa2416112?query=TOC. No photo description available. Jose Luis ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
DOI: 10.1056/NEJMoa2509426. #VTE #Anticoagulation #Apixaban #HIProTrial #Cardiology #Thrombosis #EvidenceBasedMedicine #ClinicalTrial https ...
org/doi/full/10.1056/NEJMoa2416112?query=TOC · No photo description available. Jose Luis Santamaria and 21 others. 22 reactions ·. 3 shares.
org/doi/full/10.1056/NEJMoa2209 051 · No photo description available. May be an image of one or more people.
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
Physiological processes (black font) and diseases (red font) in which eosinophils are implicated. Very informative ERS Monograph on ...
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
BavenoVII Prevention of bleeding from varices The winner is CARVEDILOL ➡️ Primary prophylaxis✓ ➡️ Secondary prophylaxis✓ Time to retire...
org/doi/full/10.1056/NEJMoa2416112?query=TOC · No photo description available. Jose Luis Santamaria and 22 others. 23 reactions ·. 3 shares.
... 10.1056/NEJMoa1113697. http://nej.md/YaI7fo. 0 reactions. Dmitry Dzhagarov ▻ ПРОФИЛАКТИКА И ЛЕЧЕНИЕ ВОЗРАСТНЫХ ЗАБОЛЕВАНИЙ. 3y · Public · Study ...
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
... Thromboembolism. N Engl J Med 2013; 368:709-718February 21, 2013DOI: 10.1056/NEJMoa1113697. NEJM.ORG. http://nej.md/YaI7fo.
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
Morbo di Buerger: l'ultima sigaretta e poi basta - EMpills - Pillole di medicina d'urgenza. 0 reactions. Profile photo of Rosanna.
Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
org/doi/full/10.1056/NEJMoa2416112?query=TOC · No photo description available. Jose Luis Santamaria and 21 others. 22 reactions ·. 3 shares.
Do Repeat COVID Infections Increase the Risk of Severe Disease or Long COVID? 8. 8 reactions ·.
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
Patients With and Without Diabetes Without Significant Angiographic Coronary Artery Disease ... OBJECTIVE The risk of myocardial infarction (MI) ...
... 10.1056/NEJMoa1113697. http://nej.md/YaI7fo. 0 reactions. Profile photo of Zsanett. Zsanett Nemesné ▻ Cardiology Club-AL- Azhar University قلب ...
It's a very interesting. Because is a new guideline. But it's just an imaging approach. (Although in the preparation of the guidelines have ...
Intensive Care Med. 2017 Jan 18. An update to "Surviving Sepsis Campaign Guidelines for Management of Sepsis and Septic Shock: 2012".
The clinical indications for the DOACs are less broad than for the vitamin K antagonists. Dabigatran, rivaroxaban, apixaban and edoxaban are ...
• DOI: 10.1056/NEJMoa2509426 One-line context: This trial demonstrates that 12 months of low-dose apixaban (2.5 mg BID) significantly ...
N
TS
AM
PC
JS
دا
さ
SE
SG
GD
DM
O
SR
PC
DR
SN
IL
TB
B
DS
JV
A
GP
DL
V
TS
F
北
M
MA
G
E
DM
LI
MP
DH
C
AG
Y循
CM
SG
抗
R
TN
CF
JM
A
C
AM
BG
EC
P
BM
RA
TV
AM
PM
FA
N
南P
CK
P
MZ
GR
D
Z
TH
A
NR
岩老
MM
TI
SC
J
SK
เม
SP
FG
M
NH
S
SI
JT
AG
ST
AM
JN
TL
AF
EJ
DP
Tا
JM
MA
SR
AF
RM
CT
CD
BM
NP
LL
MM
C
EN